Budget Impact Analysis of rFVIII Glycopegylated-Exei for the Treatment of Haemophilia A in Colombia

OBJECTIVES: To calculate the budget impact of introducing rFVIII glycopegylated-exei for the management of previously treated patients with haemophilia A in the Colombian health system

METHODS: The model was developed using the best practice guidelines of ISPOR and populated using the Colombian institutional health market for the prophylactic treatment of haemophilia A. There are two scenarios of comparison: 1) versus standard half-life (SHL) and extended half-life (EHL) rFVIII available in the Colombian market (750 patients) and, 2) Only EHL rFVIII (84 patients). Both scenarios used local data from The National Administrative Department of Statistics (DANE) and epidemiological data from the public and official records of the High-Cost Account (CAC). Annual bleeding rates and dosage schemes were obtained from the Colombian regulatory agency. Prices were extracted from the Medicine Price Information System (SISMED) and expressed in US dollars (USD) for a 3-year horizon and the perspective was from the Colombian health system. Probabilistic and deterministic sensitivity analysis were implemented

RESULTS: For both scenarios, the inclusion of rFVIII glycopegylated-exei resulted in savings. For the first scenario (SHL and EHL), the savings resulted in USD 30,120, USD 57,208, and USD 183,217 for the first, second, and third year, respectively, and for the second scenario (Only EHL), the savings are USD 16,819, USD 138,638 and USD 233,120 for the first, second and third year. As an extra analysis, the number of additional patients that could be treated using the first scenario during the three years due to savings are 3.6 patients

CONCLUSIONS: The inclusion of rFVIII glycopegylated-exei in the Colombian health system can result in savings of up to USD 270,545 over a 3-year horizon used for the treatment of patients with haemophilia A in prophylaxis